Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review Ou ShaJunfei NiuWenqi Jiang Review Article Open access 03 February 2013 Pages: 1387 - 1393
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types Carolyn D. Britten Review Article 27 February 2013 Pages: 1395 - 1409
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin Yutaka UedaTakayuki EnomotoTadashi Kimura Original Article 21 March 2013 Pages: 1411 - 1416
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma Stephen L. ChanChi-Hang WongWinnie Yeo Original Article 02 April 2013 Pages: 1417 - 1425
Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan Kenjiro AogiYoshiaki RaiShigemitsu Takashima Original Article 28 March 2013 Pages: 1427 - 1433
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer Jin Won KimHyun Jin ChoYung-Jue Bang Original Article 30 April 2013 Pages: 1435 - 1443
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901 Young Hak KimMasataka HirabayashiMichiaki Mishima Original Article 27 March 2013 Pages: 1445 - 1451
The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats Feng YouJinping HuYan Li Original Article 05 April 2013 Pages: 1453 - 1462
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer LucĂa CortejosoMarĂa I. GarcĂaLuis A. LĂłpez-Fernández Original Article 31 March 2013 Pages: 1463 - 1472
Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors J. F. DeekenB. ShimkusS. Zhang Original Article 16 April 2013 Pages: 1473 - 1483
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer Davendra P. S. SohalJames M. MetzPeter J. O’Dwyer Original Article 27 March 2013 Pages: 1485 - 1491
Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases Takaaki TokitoTakehito ShukuyaNobuyuki Yamamoto Original Article 27 March 2013 Pages: 1493 - 1498
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer Amita PatnaikKyriakos P. PapadopoulosAby Buchbinder Original Article 30 March 2013 Pages: 1499 - 1506
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia Siobhan HayesPaul N. Mudd Jr.Ekaterina Gibiansky Original Article 06 April 2013 Pages: 1507 - 1520
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients Masashi KanaiYoshihiko OtsukaHiroyuki Shibata Original Article 30 March 2013 Pages: 1521 - 1530
Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy Elisabeth G. VichayaXin Shelley WangPatrick M. Dougherty Original Article 31 March 2013 Pages: 1531 - 1540
Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats Cuirong ZhaoYuanyuan LiWenbao Li Original Article 06 April 2013 Pages: 1541 - 1550
Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding David S. HydockChia-Ying LienReid Hayward Original Article 09 April 2013 Pages: 1551 - 1560
Bevacizumab and central nervous system (CNS) hemorrhage Nathalie LetarteLinda R. BresslerJohn L. Villano Original Article 06 April 2013 Pages: 1561 - 1565
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo Aluvia M. EscalanteRyan T. McGrathTerry H. Landowski Original Article 10 April 2013 Pages: 1567 - 1576
Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma Ya Hua ZhongJing DaiYun Feng Zhou Original Article 03 April 2013 Pages: 1577 - 1583
Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil Weidong JiaZhiqiang ZhuQiaohong Duan Original Article 16 April 2013 Pages: 1585 - 1590
Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer Hyeong Su KimJung Han KimDae Ro Choi Original Article 09 April 2013 Pages: 1591 - 1597
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies Daryl SonnichsenDavid J. DorerFrank G. Haluska Original Article Open access 23 April 2013 Pages: 1599 - 1607
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer Kyu-pyo KimHo-Sook KimTae Won Kim Original Article 18 April 2013 Pages: 1609 - 1617
Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study Molouk HadjibabaieShirinsadat BadriArdeshir Ghavamzadeh Original Article 16 April 2013 Pages: 1619 - 1627
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer Robert AmatoMika StepankiwPatricia Gonzales Original Article 21 April 2013 Pages: 1629 - 1634
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors Antoinette R. TanDarlene G. GibbonJoseph J. Stephenson Original Article 01 May 2013 Pages: 1635 - 1643
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors Noboru YamamotoHiroshi NokiharaTomohide Tamura Original Article 25 April 2013 Pages: 1645 - 1655
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer Taishi HataMutsumi FukunagaMasaki Mori Clinical Trial Report 31 March 2013 Pages: 1657 - 1663